Phylogenetic analysis of platelet-derived growth factor by radio- receptor assay by unknown
RAPID  COMMUNICATIONS 
Phylogenetic Analysis of Platelet-derived Growth 
by Radio-receptor Assay 
Factor 
JAI  PAL  SINGH, MARGERY A.  CHAIKIN,  and CHARLES D.  STILES 
Laboratory of Tumor  Biology, Group W, Sidney Farber Cancer  Institute, and Department of Microbiology  and Molecular Genetics, 
Harvard Medical School, Boston, Massachusetts 02115 
ABSlRACt  Competition between  12Sl-labeled  platelet-derived growth factor  (PDGF)  and  unlabeled 
PDGF  forms  the basis  of  a specific  "radio-receptor assay" for quantifying PDGF  in  clotted  blood 
serum.  Human  clotted  blood  serum  contains  15  ng/ml  of  PDGF  by  radio-receptor  assay; this 
corresponds  to  a  PDGF  content  of  ~7.5  x  10  -5  pg  per  circulating  platelet,  a  figure  which  is 
corroborated by purification data. 
Clotted  blood sera from  mammals, lower vertebrates and  marine invertebrates were screened for 
homologues of human PDGF  by radio-receptor assay. All tested specimens from  phylum Chordata 
contain a mitogenic agent that competes with human PDGF for receptor binding. Sera from tunicates 
down on  the chordate line of evolution and  sera from  all tested animals on  the arthropod  line of 
development were negative. The phylogenetic distribution of  PDGF  homologue does not correlate 
with platelet distribution since platelets and their precursor cell--the bone marrow megacaryocyteu 
are unique to the mammalian hematopoietic system. One anatomical feature appearing coordinately 
with PDGF on the vertebrate line of development is a pressurized circulatory system. The coincidental 
appearance  of  these  features  may  lend  support  to  the  hypothesis  that  PDGF  plays  a  role  in 
maintenance and repair of the vascular lining in vivo. 
Platelet-derived growth factor (PDGF) is a heat-stable, cationic 
polypeptide  which  has  been  purified  to  homogeneity  from 
clinically outdated human blood products (1-3). At concentra- 
tions of 10  -l° M  or less,  PDGF stimulates  the replication of 
fibroblasts (1), glial cells (2), and other connective tissue cells 
(4) in vitro. PDGF is contained within the alpha-granules of 
circulating  Mood platelets  (5-7)  and  is  released  into  serum 
when whole blood is allowed to clot (8, 9). Thus clotted blood 
serum supports the growth of fibroblasts and connective tissue 
cells in vitro and is conventionally used as a  supplement  for 
cell culture  media;  platelet-poor  plasma  (prepared  from un- 
clotted  blood)  is  deficient  in  PDGF  activity  and  has  been 
shown to be an inefficient medium supplement for fibroblasts 
and connective tissue cells (8-11). 
Since its discovery, PDGF has been quantified by virtue of 
its capacity to stimulate the growth of connective tissue cells in 
vitro (1-3, 8, 9). These "bioassays" are reliable for purified or 
partially purified preparations. However, whole blood samples, 
crude platelet lysates, and tissue biopsies contain a variety of 
agents  other  than  PDGF  which  stimulate  replicative  DNA 
synthesis and cell division in cultured fibroblasts. These include 
epidermal growth factor (12), prostaglandins (13), insulin (14), 
and somatomedins (15). Thus, there have been no unambigu- 
ous  estimates  of the  PDGF  content  of common  biological 
fluids such as blood or platelet-poor plasma.  A  radioimmu- 
noassay for PDGF has been described but the assay has not 
been applied to blood samples (16). 
Recently, it has been shown that PDGF, like other growth 
factors,  exerts  its  biological effects  through  interaction  with 
specific,  high-affinity receptors associated with its target cells 
(4,  17-20). We exploited the PDGF:receptor interaction in a 
sensitive and highly specific "radio-receptor assay" for quan- 
tification of PDGF. This assay is based upon the competition 
of unlabeled PDGF with homogeneous preparations of human 
L25I-labeled PDGF for binding to the PDGF-specific receptor 
associated with BALB/c-3T3 cells. Here we describe the radio- 
receptor assay for PDGF and provide estimates of the PDGF 
content of human platelets and of human clotted blood serum; 
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PDGF  appeared  suddenly  with  the  first  chordates  and  has 
been highly conserved since that time. 
MATERIALS  AND  METHODS 
Cell Culture 
Stock cultures of BALB/c-3T3 cells (clone A-31) were maintained as previ- 
ously described (1). PDGF-binding studies were conducted on confluent, density- 
arrested monolayers of BALB/c-3T3 cells in 35-ram diameter culture dishes at a 
density of 4-5 x  l05 cells/cm ~. 
PDGF 
Human PDGF was purified to homogeneity by a modification of  our previous 
protocol which employs high performance liquid chromatography (HPLC) at two 
stages. We employed reverse-phase chromatography on an HPLC C-18 column 
(Micromeritics Instruments Co., Norcross, GA) and molecular sieving chroma- 
tography on an HPLC sizing column (Waters Associates, Milford, MA) in lieu of 
the isoelectric focussing and SDS gel electrophoresis steps described earlier (l). 
The revised protocol yields material which appears as a single band of  molecular 
weight 33,000-daltons by SDS gel electroplioresis and  is mitogenic at protein 
concentrations of < l ng/ml. 
Radio-iodination 
The human PDGF was labeled with ~251 by the Hunter-Greenwood procedure 
(21). The iodination reaction was terminated and the free ~2~I was removed by 
rapidly passing the samples through the Waters HPLC sizing column. Specific 
activity of the radio-labeled PDGF ranged from 0.2 to 0.3 tool I per tool PDGF 
in various preparations. The radio-labeling procedure did not alter the mitogenic 
activity of PDGF as assayed on BALB/c 3T3 cells under standard conditions (1). 
Serum and Plasma Samples 
Blood was drawn from larger animals by cardiac puncture or venipuncture. 
Blood was collected from some smaller animals by slicing major vessels with a 
scalpel. Sea urchins were bled from the coelomic cavity by needle aspiration. 
Clotted lobster hemolyph  was purchased  commercially (Gibco  Laboratories, 
Grand Island Biological Chemical Co., Grand Island, NY). Clotted blood serum 
was prepared by allowing freshly drawn blood to clot at 37°C (warm blooded 
animals) or at  room  temperature  (cold blooded  animals).  Unclotted  human 
platelet-poor plasma was prepared as previously described (1). All serum and 
plasma  samples were heat-treated  at  56°C  for  30  min  and dialyzed  against 
Dulbecco's modified eagle's medium (DME) before use in the binding assay. 
Receptor Binding Assay 
To avoid the complexities introduced by modulation of receptor content at 
37°C (22-25), binding studies were conducted at 4°C where true equilibrium 
conditions can  be  approached  and  sustained. At  4°C,  cell-associated PDGF 
approaches saturation  within 2 h  (data  not  shown). To initiate the  receptor 
binding assay, 3T3 cell monolayers were washed twice with PBS. The washed 
monolayer cultures were incubated at 4"C in DME containing  1 mg/ml BSA, 
~25I-PDGF, and  (when  indicated)  blood  samples being  assayed  for  receptor 
binding activity. Total volume of the binding assay mixtures was 700/zl. The 
culture plates were gently agitated during the course of the binding action. After 
2 h  at 4°C,  the  binding  medium  was aspirated.  Unbound radioactivity was 
removed by washing the monolayers four times with PBS containing BSA (1 
mg/ml).  Cell-associated radioactivity was then solubilized in a mixture of 1% 
Triton X- 100 and 10% glycerol and counted. Nonspecific binding was determined 
by incubating the ~25I-PDGF tracer with a  100-fold molar excess of unlabeled 
PDGF. 
RESULTS 
Scatchard Analysis of the 
PDGF:Receptor Interaction 
The binding of human 12~I-PDGF preparations to confluent 
monolayers of BALB/c-3T3  ceils  is  saturable  (Fig.  1,  inset). 
Scatchard  plot analysis (26)  (Fig.  1)  indicates  approximately 
160,000  PDGF  receptors  per  3T3  cells  with  an  equilibrium 
dissociation  constant  (kd)  of  5  X  10  -m  M.  These  binding 
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which  time  cell-associated  radioactivity was  determined  as  de- 
scribed  in  Materials  and Methods.  Specific  binding  (inset;  0)  is 
plotted after correction for nonspecific  binding (inset;  O)  deter- 
mined in  the presence of a 100-fold  excess of  unlabeled PDGF. 
Although  PDGF is  a "sticky"  protein which  binds  to  laboratory 
plasticware under some conditions (18), the amount of nonspecific 
binding in these studies was low as has been noted by others (4, 17, 
19, 20). We have found that PDGF does not adhere nonspecifically 
to plastic culture dishes that have been used  for cell culture because 
serum-supplemented  culture  medium contains  a substance  (not 
PDGF) which coats the dishes and eliminates adventitious binding 
(Singh and Stiles, unpublished observations). 
characteristics  of BALB/c-3T3 cells  are  similar  to those  re- 
ported for Swiss 3T3 cells by Huang et al. (19) and for human 
fibroblasts by Heldin et al. (17). Data of Bowen-Pope and Ross 
(4)  are in accord with respect to receptor number.  However, 
the later workers have reported dissociation constants some 50- 
fold lower than those described here and elsewhere  (17,  19). 
The basis of this discrepancy is unclear. 
Specificity of the PDGF:Receptor Interaction 
The PDGF receptor exhibits stringent specificity (Fig. 2). A 
10-fold molar excess of unlabeled human PDGF quantitatively 
competes  with  '~°I-PDGF  for  binding  to  3T3  cells.  Other 
growth factors (EGF,  pituitary fibroblast growth factor) and 
other platelet-specitic proteins (platelet factor IV, beta-throm- 
boglobulin) do not compete with  125I-PDGF  for receptor oc- 
cupancy even  at  high  molar  excess  (Fig.  2).  Clotted  blood 
serum from humans does compete for receptor occupancy (Fig. 
2, inset). The dose-response curve of human serum parallels 
that  of the  PDGF  standard,  indicating  that  the  competing 
material in the serum sample is PDGF. 
Quantification of PDGF in Mammalian 
Blood Preparations 
The data presented in Fig. 2 indicate that competition be- 
tween unlabeled PDGF and x~SI-PDGF for occupancy of re- 
ceptors on BALB/c-3T3 monolayer cultures could allow quan- 
tification of PDGF in blood samples. A standard reference can 
be generated  by admixing known quantities  of pure  PDGF 
with  a  fixed  concentration  of 12sI-PDGF before  incubation 
with 3T3 monolayers (Fig. 3). When human serum (100%)  is 
admixed with the x2sI-'PDGF, competition equivalent to 15 ng/ 
ml of pure PDGF is observed; by contrast, unclotted human 
platelet-poor plasma contains ~ 1 ng/ml of PDGF (Fig. 3). The 
low concentration  of PDGF  in  human  plasma  is  consistent 
with a variety of data showing that human PDGF is contained 
in the alpha granules of platelets  (5-7) and is released  only 
when blood clots (8, 9). Assuming (a) a  normal platelet count 
of 200,000/ram  a  and  (b)  total  release  of PDGF  during  clot -~  08 
o 
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FIGURE  2  Specificity of the PDGF:receptor interaction. 4 ng of r251- 
PDGF (specific activity 8,000 cpm/ng) were admixed with the indi- 
cated quantities of  unlabeled PDGF  (0),  epidermal growth  factor 
(I),  pituitary fibroblast growth factor (i-I),  piatelet factor IV (A), or 
beta-thromboglobulin  (*).  Binding  of  the  1251-PDGF to  3T3  cell 
monolayers at 4°C was then determined as described in  Materials 
and Methods. (Inset) Same as above except that 8 ng of the a2sl- 
PDGF  tracer were  admixed with  unlabeled  PDGF  (O)  or  human 
serum  (O).  The units on the abscissa are ng x  10  -1  for  PDGF  and 
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FIGURE  3  Quantifica- 
tion of  PDGF  in  serum 
samples  by  radio-re- 
ceptor  assay.  Between 
300  and 400 #1  of each 
sample  were  admixed 
with  8  ng of 12SI-PDGF 
(sp  act  6,000  cpm/ng). 
The  samples  were  ad- 
justed to a final volume 
of 700 ~ with  DME--1% 
BSA. Specific binding of 
the 12SI-PDGF to 3T3 ceii monolayers was determined as described 
in Materials and Methods. The standard curve for the radio-receptor 
assays was established from binding assays conducted with 8 ng of 
the 12SI-PDGF and the indicated quantity of unlabeled PDGF. The 
indicated  PDGF  content of the serum  samples was read from  the 
standard  curve  and  normalized  to  100% concentration.  Human 
platelet-poor plasma which  contains very little  PDGF  activity was 
actually assayed at 100% concentration. The numbers in parentheses 
indicate the number of determinations done for each sample. Ex- 
perimental variation in these determinations was <5%. 
formation, it may be calculated that each circulating platelet 
contains 7.5  x  10  -5 pg of PDGF. This figure is in very close 
agreement  with  an  independent  estimate  of  5  ×  10  -~  pg/ 
PDGF/platelet  which  can  be  calculated  from  our  original 
PDGF  purification data (1).  The  latter calculation is  based 
upon the normalized recovery of pure PDGF from 500 U  of 
clinically outdated human platelets (where  1 U  of platelets is 
equivalent to -250 ml of blood). 
Clotted blood serum from a variety of other mammals was 
assayed for homologues of human  PDGF.  On  a  volumetric 
basis, these mammalian sera are all roughly as potent as human 
serum for competitive inhibition of ]25I-PDGF binding. Assum- 
ing that the equilibrium dissociation constants for PDGF ham- 
plagues in animal serum are identical to that of human PDGF, 
the PDGF homologue content of the samples ranges from 4 to 
26 ng/ml (Fig. 3, inset). 
Phylogenetic Survey for Homologues of 
Human PDGF 
Clotted blood sara from a  variety of lower vertebrates and 
marine invertebrates were screened for homologues of human 
PDGF by radio-receptor assay and the results are summarized 
(Fig.  4).  Material  which  competes  with  125I-labeled  human 
PDGF  for  binding  to  specific receptors can  be  detected in 
blood from all members of phylum Chordata. For lower char- 
dates, the potency of the sera and the calculated PDGF ham- 
plague concentrations are remarkably similar to those noted 
for  mammalian  and  human  sera.  Below  phylum  Chordata, 
none of the sara contains a detectable PDGF homologue. 
Correlation between Receptor-Binding Activity 
and Mitogenic Activity 
As  independent  documentation  of the  PDGF  homologue 
content in blood samples, all sera were assayed for PDGF-like 
mitogenic  activity on  microtiter  cultures  of 3T3  cells.  The 
accord between the  radio-receptor assay for PDGF  and  the 
bioassay was  very good.  A  detailed comparison of the  two 
assays is shown in Fig. 5 for sera from two lower vertebrates 
(chicken,  skate)  and  several  marine  invertebrates  (starfish, 
Maia, Limulus).  Human clotted blood serum and human plate- 
let-poor plasma are also compared. The vertebrate sera inhibit 
the binding of 12~I-PDGF to 3T3 cells (Fig. 5, upper) and are 
potent mitogens in the concentration range of 10-20% (Fig. 5, 
lower). By contrast, the sera from marine invertebrates display 
neither binding nor mitogenic activity. Human  platelet-poor 
plasma displays very weak binding inhibition activity, as noted 
previously (Fig. 3), and very weak mitogenic activity. 
DISCUSSION 
Clotted blood sera  from  old world  monkeys  down  through 
jawless fish in phylum Chordata inhibit the binding of human 
~25I-PDGF  to specific receptors on cultured mouse fibroblasts 
(Fig. 4). The specificity  of the PDGF radio-receptor  assay (Fig. 
2) together with good correlation between the radio-receptor 
assay and bioassay data (Fig. 5) supports the conclusion that 
a homologue of human PDGF exists in dotted blood sera from 
all members of phylum Chordata. In humans, between 5 and 
7.5  X  l0  -5 pg of PDGF are contained in the average platelet. 
The cellular source of PDGF in lower vertebrates is unclear 
since  platelets  (and  their  precursor  cell,  the  bone  marrow 
megacaryocyte) are unique features of the mammalian hema- 
tapoietic system (27). 
The failure to detect a PDGF homologue outside of phylum 
Chordata (Figs. 4  and 5) can be interpreted in either of two 
ways.  It  is  possible that  serum  from  many  or  all  of these 
animals contains a homologue of  PDGF but that below phylum 
Chordata the proteins are so structurally divergent from human 
PDGF that they do not bind to the mammalian PDGF recep- 
tor. The alternate view is that a PDGF-like peptide appeared 
suddenly with the first chordates, served a  function, and was 
stringently preserved through subsequent selection. The fossil 
record indicates that the time interval between the appearance 
of fishes and the appearance of man (about 350 million years) 
far  exceeds the  time  interval from  invertebrates to  the  first 
fishes (no more than  100 million years). The observation that 
PDGF homologue titers drop abruptly after remaining nearly 
invariam  from  mammals  down  through  fish  thus  argues  in 
favor of the  view that  PDGF  appeared coincidentally with 
chordates and was subsequently preserved. If this is true (and 
the  conclusion  is,  of course,  speculative) it  is  of interest  to 
consider developmental advances in the chordates which could 
have dictated the need for a PDGF-Iike mitogen. 
As noted above, the phylogenetic distribution of PDGF does 
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FIGURE 4  Phylogenetic survey of 
PDGF-like  material  in  clotted 
PDGF  blood  serum.  Clotted  blood  se- 
(ng/rnl]  rum  was  collected  from  animal 
ILimulus  <t  donors  and  for  assayed  PDGF 
content by radio-receptor assay as 
described in Materials and Meth- 
INereis(blood)  <t  ads.  All  of  the  invertebrate sera 
Annelids-~l  (coelomic~  /~lermsk  <t b  were  assayed at  final  concentra-  fluid  / 
lions  of  50-70%  in  an  effort  to 
detect  trace  quantities  of  PDGF 
MoIlusks---lMaia  <l  homologue.  Results  of  the  radi- 
i  oreceptor  assay  have  been  nor- 
realized to a serum concentration 
of  100%.  (a)  Lamprey blood  was 
from  Petromyzon marinus.  The 
adult  form  of  this  animal  is  a 
blood-sucking  parasite;  however, 
the blood was collected from the 
filter-feeding  juvenile  form  (am- 
mocoetes) and from  newly trans- 
I  formed  adults  which  had  never 
ProtozoansN.T  fed  upon  blood.  (b)  These  ani- 
mals are difficult to bleed because they are small. The blood samples were contaminated with contents of the gut which caused 
the 3T3 cell monolayers to detach from culture dishes at the high concentration (50-70%) employed in the receptor binding assay. 
At concentrations of 20% and less there was no toxicity. At these lower concentrations the samples were totally negative for PDGF 
activity by bioassay. Since the bioassay actually detects some mitogenic activity in human platelet-poor plasma at 20% (see Fig. 5) 
and since human platelet-poor plasma contains ~1 ng/ml of PDGF by the radio-receptor assay (Fig, 3), we infer that these samples 
have <1  ng/ml of PDGF homologue. 
t00~  eHuman  Serum 
o Human Platelet Poor Plasma 
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FIGURE  5  Sara which  compete with  ~2sI-PDGF  for receptor occu- 
pancy are mitogenic.  Upper panel. Representative vertebrate and 
invertebrate blood  samples  at the  indicated  concentrations  were 
admixed with 1251-PDGF (8-10 ng/ml). Binding of 12sI-PDGF  to 3T3 
cell  monolayers was  then  assayed  as described  in  Materials  and 
Methods. Data are plotted as "percent binding inhibition"  relative 
to controls incubated with ~251-PDGF only. Lower panel. Quiescent, 
density-arrested  monolayer cultures  of 3T3 cells were prepared in 
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not correlate  with  the distribution  of the platelet/megacary- 
ocyte cell system (27). Nor does the PDGF homologue correlate 
with clotting ability because clotting is a ubiquitous function 
of vertebrate and invertebrate blood (27). One possibly relevant 
development  coinciding  with  the  appearance  of PDGF-Iike 
material is the blood pressure produced in animals featuring 
both a closed circulatory system and a chambered heart. Closed 
circulatory  systems  appear  at  several  points  in  the  animal 
kingdom and are featured byNereis, Amphioxus, and all char- 
dates  (Fig.  3)  (28).  Chambered  hearts  are  seen  in  mollusks 
(Maia) as well  as  in  chordates  (Fig.  3)  (28).  However,  only 
phylum Chordata is uniformly characterized by the combina- 
tion of a chambered heart and a closed circulatory system (28). 
The luminal surface of blood vessels in chordates is subject to 
abrasion from cells  and fluid  moving under pressure  and at 
high speed. It is possible that a serum mitogen such as PDGF 
became necessary to regulate repair of such damage. This view 
of the phylogenetic  data is consistent  with  a  hypothesis  ad- 
vanced by Ross and his co-workers (8, 29) on totally independ- 
ent grounds to the effect that a platelet-derived  mitogen such 
as PDGF  functions  in viva to  repair  damage  to  the vascular 
lining. 
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